Anaphylaxis and Related Events Following COVID‐19 Vaccination: A Systematic Review

Abstract

The Coronavirus Disease 2019 (COVID‐19), induced by the SARS CoV‐2 virus, is responsible for a global pandemic following widespread transmission and death. Several vaccines have been developed to counter this public health crisis using both novel and conventional methods. Following approval based on promising efficacy and safety data, the AstraZeneca, Janssen, Moderna, Pfizer/BioNTech, and SinoVac vaccines have been administered globally among different populations with various reported side effects. Reports of life‐threatening anaphylaxis following administration were of particular concern for both healthcare providers and the public. A systematic literature search using PubMed, Embase, Scopus, Web of Science, Science Direct, MedRxiv, and Lens.org databases identified relevant studies reporting anaphylaxis following vaccine administration. This systematic review includes 41 studies reporting anaphylaxis out of 19908 studies that were retrieved for screening. A total of 7942 cases, including 43 deaths, were reported across 14 countries. Most cases occurred following the administration of the first dose. Importantly, the benefits of vaccination far outweigh the risks of anaphylaxis. Subsequently, as populations continue to get vaccinated, it is important for healthcare providers to be able to recognize individuals at risk of developing anaphylaxis. Furthermore, they must be familiar with both the clinical hallmarks and treatment of anaphylactic reactions to minimize long term sequalae and prevent death in vaccinated individuals. This article is protected by copyright. All rights reserved

Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review

“…Despite initial concerns of various adverse events stemming from accelerated production and distribution of the various SARS-CoV-2 vaccines [ 66 – 69 ], they have undoubtedly been the most effective shield against this pandemic [ 70 – 72 ], estimated to have prevented 20 million deaths in the first year of roll-out alone [ 73 ]. Vaccines were shown to act as a booster in those previously infected by eliciting a similar titer count compared to infection-naïve individuals receiving 2 doses [ 74 , 75 ], while also providing more durable protection in such individuals [ 76 , 77 ].…”

Leveraging artificial intelligence to optimize COVID-19 robust spread and vaccination roll-out strategies in Southern Africa

“…Although this has led to the identification of various COVID-19 vaccine candidates, the high and growing demand for the vaccine has become a challenge (Bubar et al, 2021 ). Among these candidates, the vaccines developed by Pfizer-BioNTech, Moderna COVID-19, Oxford-AstraZeneca COVID-19, Sinovac COVID-19, and Johnson & Johnson COVID-19 have received Emergency Use Authorization (EUA) from regulatory bodies in the UK, Europe, USA, China, and India (Acharya et al, 2021 ; Kalinke et al, 2022 ; Mushtaq et al, 2022 ; Paul et al, 2022 ). It has been demonstrated that these vaccines can provide reasonable levels of protection against symptomatic and severe disease with two doses administered 3–4 weeks apart (Polack et al, 2020 ; Baden et al, 2021 ; Dagan et al, 2021 ).…”

Identification of Actual Bibliometric/Scientometric Issues Based on 2018-2022 Data from the Lens Platform by Building Key Term Co-occurrence Network

“…The authors [6] conducted a systematic search of the literature using PubMed, Embase, Scopus, Web of Science, Science Direct, MedRxiv, and Lens.org databases, which contained studies reporting anaphylaxis after vaccine injection. The conducted systematic review included 41 studies which reported anaphylaxis.…”